Day: January 14, 2023
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks)
Efficacy was consistent over time across all endpoints, and no lessening of response (no tachyphylaxis) from roflumilast cream was observed
Long-term IGA success and Intertriginous-Investigator Global Assessment (I-IGA) success results are consistent with results from the DERMIS-1 and DERMIS-2 Phase 3 clinical trials
Roflumilast cream was very well-tolerated, with low rates of discontinuations due to either adverse events or lack of efficacyWESTLAKE VILLAGE, Calif., Jan. 14, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing...